ClinicalTrials.gg
Not yet recruitingNCT04538274Updated Feb 20, 2025

Trained Patient Involvement to Promote the Resumption of CPAP in Patients Who Have Discontinued Its Use

An interventional study of peer-driven intervention in Obstructive Sleep Apnea Syndrome, sponsored by AGIR à Dom. Not yet recruiting. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by AGIR à Dom · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Study summary

The primary objective of this randomized clinical trial is to evaluate the role of patient researchers in promoting the resumption of CPAP therapy in apneic patients who had previously stopped CPAP

Read the detailed description

Obstructive Sleep Apnoea syndrome (OSA) is one of the most frequent chronic disease presenting with or without symptoms of excessive daytime sleepiness (EDS) and being accompanied by neurocognitive, cardiovascular and metabolic complications.

The first line therapy of obstructive sleep apnoea is continuous positive airway pressure (CPAP). CPAP is highly effective in symptomatic patients for reducing EDS and improving daily functioning, cognitive function, mood and quality of life. However, success of CPAP treatment is hampered by long term nonadherence in nearly half of patients. Non adherence to CPAP is less and less related to technical problems, but rather to users' profile, their representations of OSA and the benefits experienced from CPAP. Cognitive-behavioural and motivation enhancement therapies can promote adherence to CPAP treatment. In addition to health professionals, patients and public involvement (PPI) is more and more advocated in the field of education and research. Nevertheless, the level of evidence regarding efficacy of PPI and patient researchers remains to be demonstrated. The aim of this randomized clinical trial is to evaluate the role of patient researchers in promoting the resumption of CPAP therapy in apneic patients who had previously stopped CPAP

02

Conditions studied

  • Obstructive Sleep Apnea Syndrome

Keywords

  • Sleep Apnea
  • CPAP adherence
  • Patient and Public Involvement (PPI)
  • cognitive-behavioural and motivation enhancement therapies
  • Patient Involvement (PI)
03

In context

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

This study's planned enrollment of 208 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

AGIR à Dom is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years old
  • Diagnosed with of severe OSA (AHI ≥ 30 events/hour)
  • Discontinuation of CPAP 4 to 12 months after initiation Followed by the home health care provider Agiradom
  • Access to a computer and/or tablet and an internet connection
  • Oral and written French
  • Able to provide written
  • Affiliated to social security or beneficiary of such a scheme

Exclusion criteria

Exclusion Criteria:

  • CPAP cessation due to a resolution of the OSAS (e.g. weight loss after bariatric surgery) or another pathology that prevents the continuation of treatment (e.g. ENT surgery, etc.).
  • Severe and/or unstable comorbidity that required hospitalisation for decompensation in the previous year (heart, kidney, respiratory, liver, psychiatric or other insufficiency).
  • Patient being treated with a mandibular advancement orthosis
  • Lack of availability (e.g. night worker or patient who travels frequently, etc.).
  • Current participation in, participation in the month prior to inclusion in another clinical intervention research study that may impact the study: this impact is left to the investigator's discretion.
  • Referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant woman, breastfeeding mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    Patient researcher intervention

    Intervention conducted by trained patient researchers to restart CPAP in addition to usual care

    Behavioral: peer-driven intervention

  • No intervention
    Usual care

    Usual care

Interventions

  • Behavioralpeer-driven intervention

    Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.

06

What researchers measure

Primary outcomes

  1. Evaluate the impact of a 6-month, peer-driven intervention to promote the resumption of CPAP after discontinuation

    The range of patients reusing CPAP in the intervention group The difference in percentages of patients who reuse CPAP between the peer-driven intervention group and the control group.

    Time frame: 6 months after inclusion

Secondary outcomes

  1. Evaluate the impact of the peer-driven intervention on adherence to CPAP compared to the control group

    the difference in CPAP compliance (average hours of use/night) between the AP intervention group and a control group

    Time frame: 6 month after inclusion

  2. Evaluate the impact of the peer-driven intervention on adherence to CPAP compared to the control group

    the difference in percentages of patients who reuse to CPAP with at least 4 hours' use /night for 70% of nights

    Time frame: 6 month after inclusion

  3. Disease-specific quality of life

    The Functional Outcomes of Sleep Questionnaire (FOSQ10) will be completed at inclusion (M0) and at the 6-month follow-up (M6). This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: At inclusion and after 6 months

  4. Patient Self-Efficacy Measure for Sleep Apnea

    The Self-Efficacy Measure for Sleep Apnea (SEMSA) questionnaire, a tool with strong psychometric properties and with the potential for identifying patient perceptions will be completed at inclusion (M0) and at the 6-month follow-up (M6). This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: At inclusion and after 6 months

  5. Patient knowledge, skill, and confidence for self-management

    The Patient Activation Measure (PAM) qestionnaire, a measure that assesses patient knowledge, skill, and confidence for self-management, will be completed at inclusion (M0) and at the 6-month follow-up (M6) This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: At inclusion and after 6 months

  6. Patient satisfaction and peer satisfaction

    Patient satisfaction with the peer-driven intervention at 6 months will be measured on a 4-point Likert scale : very dissatisfied, dissatisfied, satisfied, very satisfied. Satisfaction of PI representatives will be measured on a 4-point Likert scale: very dissatisfied, dissatisfied, satisfied, very satisfied.

    Time frame: At 6 month after inclusion

  7. Feasibility and the execution of the peer-driven intervention

    Evaluate the feasibility and the execution of the peer-driven intervention

    Time frame: At 6 month after inclusion

  8. Age

    This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  9. Gender

    This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  10. BMI Body Mass Index

    This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  11. marital status with infants (<10 years) or not

    This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  12. Education level

    This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  13. employment and socio-professional status

    This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  14. alcohol-smoking status

    This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  15. fragility and social precariousness

    EPICES score will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  16. medication adherence

    Girerd Score. This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  17. OSA history

    date of diagnosis of OSA

    Time frame: inclusion

  18. CPAP treatment

    Date of initiation of CPAP and date and cause of CPAP discontinuation

    Time frame: inclusion

  19. Baseline Apnea-Hypopnea Index (AHI)

    This variable will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  20. Excessive daytime sleepiness (EDS score)

    Epworth Sleepiness Scale will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

  21. Comorbidities

    Charlson index will be used to assess predictors of positive response to patient researcher intervention

    Time frame: inclusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Merle R, Pison C, Logerot S, Deschaux C, Arnol N, Roustit M, Tamisier R, Pepin JL, Borel JC. Peer-driven intervention to help patients resume CPAP therapy following discontinuation: a multicentre, randomised clinical trial with patient involvement. BMJ Open. 2021 Oct 14;11(10):e053996. doi: 10.1136/bmjopen-2021-053996. PubMed 34649850 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 0 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Sep 4, 2020
StartEst.
Feb 18, 2025
Primary completionActual
Feb 18, 2025
CompletionEst.
Feb 18, 2025
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04538274
Lead sponsor
AGIR à Dom
Responsible party
Sponsor
First posted
Sep 4, 2020
Start date
Feb 18, 2025 (estimated)
Primary completion
Feb 18, 2025
Completion
Feb 18, 2025 (estimated)
Last update
Feb 20, 2025

Study contacts

Christophe Pison, MD
Contact
CPison@chu-grenoble.fr
04 76 76 54 53 ext. +33
Raymon Merle
Contact
raymond.merle38@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion